Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15852 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2ACYP11B1 | |
| SCHEMBL39674 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2ACYP11B1 | |
| SCHEMBL9044783 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2ACYP11B1 | |
| Benzene SCHEMBL1225975 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2ACYP11B1 | |
| SCHEMBL16162331 | 0.97 | IDO1 (0.50) | IDO1PAMMAOBHTR2ACYP11B1 | |
| SCHEMBL16162329 | 0.97 | IDO1 (0.50) | IDO1PAMMAOBHTR2ACYP11B1 | |
| Ammonia Solution, Strong SCHEMBL3755403 | 0.97 | IDO1 (0.50) | IDO1PAMMAOBHTR2ACYP11B1 | |
| 1,1-Dichloroethene SCHEMBL9741142 | 0.89 | PAM (0.48) | IDO1PAMMAOBHTR2A | |
| SCHEMBL10880315 | 0.89 | IDO1 (0.44) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| Styrene SCHEMBL1507248 | 0.89 | ALDH1A1 (0.58) | IDO1PAMMAOBHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459727-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2011012632-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | HDHD5, PAH, GRHPR | IDO1 464/4885PAM 569/4885MAOB 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.